Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7276MR)

This product GTTS-WQ7276MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7276MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13775MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ3776MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ10509MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ8857MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ555MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 4D5-8
GTTS-WQ808MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ12874MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ9715MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW